Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Changchun BCHT Biotechnology Co. (688276.SS)
CNY15.25
+0.29 (+1.94%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
1260 Huoju Road 130103
Changchun, CN
Changchun, CN
CEO
Chunlai Jiang
Website
bchtpharm.com
IPO
2021-06-25
ISIN CNE100005XY6
Description
Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical enterprise primarily focused on the research, development, production, and global commercialization of vaccines designed for human use. Its extensive product portfolio features key immunizations such as attenuated (live) herpes zoster and varicella vaccines, alongside a live, nasal, and freeze-dried influenza vaccine, and a rabies vaccine utilizing vero cell technology. This company was established in 2004 and is headquartered in Changchun, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY15.25
+0.29 (+1.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.09
Float Shares
53.51M
Free Float %
22.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.53% | -5.23% | -12.22% | -18.75% | -26.02% | -15.43% | -24.41% | -76.46% | -86.54% | -86.54% | -86.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.25
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.06
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-50.8% Q1'26: -9.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-217.9% Q1'26: -423.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-8.5% Q1'26: -38.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-56.7% Q1'26: +0.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-8.8% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.5% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.02× Q1'26: 93.09× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.20B
est: 1.33B (-9.8%)
|
1.07B
est: 1.21B (-11.7%)
|
1.82B
est: 1.88B (-3.1%)
|
1.23B
est: 1.94B (-36.7%)
|
605.07M
est: 1.35B (-55.1%)
|
745.00M
745.00M – 745.00M
-44.7% YoY
|
813.00M
813.00M – 813.00M
+9.1% YoY
|
874.00M
874.00M – 874.00M
+7.5% YoY
|
| EBITDA |
330.40M
est: 418.81M (-21.1%)
|
268.78M
est: 381.17M (-29.5%)
|
656.61M
est: 295.63M (+122.1%)
|
361.65M
est: 304.60M (+18.7%)
|
-239.01M
est: 211.43M (-213.0%)
|
116.94M
116.94M – 116.94M
-44.7% YoY
|
127.61M
127.61M – 127.61M
+9.1% YoY
|
137.19M
137.19M – 137.19M
+7.5% YoY
|
| EBIT |
262.06M
est: 336.22M (-22.1%)
|
197.84M
est: 305.99M (-35.3%)
|
564.62M
est: 133.50M (+322.9%)
|
257.47M
est: 137.55M (+87.2%)
|
-343.19M
est: 95.47M (-459.5%)
|
52.81M
52.81M – 52.81M
-44.7% YoY
|
57.62M
57.62M – 57.62M
+9.1% YoY
|
61.95M
61.95M – 61.95M
+7.5% YoY
|
| Net Income |
243.55M
est: 359.19M (-32.2%)
|
181.54M
est: 301.72M (-39.8%)
|
501.01M
est: 522.09M (-4.0%)
|
232.09M
est: 544.14M (-57.3%)
|
-272.07M
est: 243.21M (-211.9%)
|
-90.69M
-90.69M – -90.69M
-137.3% YoY
|
-12.37M
-12.37M – -12.37M
+86.4% YoY
|
28.86M
28.86M – 28.86M
+333.3% YoY
|
| SGA |
555.93M
est: 540.03M (+2.9%)
|
552.73M
est: 491.48M (+12.5%)
|
800.93M
est: 949.36M (-15.6%)
|
582.83M
est: 978.17M (-40.4%)
|
380.45M
est: 678.96M (-44.0%)
|
375.52M
375.52M – 375.52M
-44.7% YoY
|
409.80M
409.80M – 409.80M
+9.1% YoY
|
440.54M
440.54M – 440.54M
+7.5% YoY
|
| EPS |
0.62
est: 0.87 (-28.5%)
|
0.44
est: 0.73 (-39.6%)
|
1.21
est: 1.27 (-4.5%)
|
0.56
est: 1.32 (-57.6%)
|
-0.66
est: 0.59 (-211.9%)
|
-0.22
-0.22 – -0.22
-137.3% YoY
|
-0.03
-0.03 – -0.03
+86.4% YoY
|
0.07
0.07 – 0.07
+333.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-719.99M
OE per share TTM
-1.74
Owner's Yield
-10.91%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
140.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.8K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.2K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 583.8K | 0.06% |
| 4 | Vanguard Total International Stock ETF VXUS | 0.00% | 682.7K | 0.05% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 5.6K | 0.10% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 938.24 | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.8K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.5K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 669.10 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 77.31 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-276.5K
Shares Outstanding
242.17M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changlin Zhu | Secretary of the Party Branch, Chairman of the Trade Union, & Chief Engineer of BaiKe Biotechnology | — | male |
| Chunlai Jiang | GM & Director | — | male |
| Dawei Liu | Deputy General Manager | — | male |
| Fu Qiang Yan | Accounting Supervisor | — | — |
| Wei Wei | Deputy General Manager | — | female |
| Xiaohui Chen | Chief Operating Specialist | — | male |
| Zang Yang | Executive Vice President of the Institute of Drug Research | — | — |
| Zhaofeng Meng | Chief Financial Officer | — | male |
| Zhe Zhang | Board Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688276.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
